Independent

[flipper44]

Curiously, ….five weeks after October 1, the last randomized patient’s data in the DCVax-l trial will have accumulated ten years of follow-up time — something that also may provide considerable information/influence to regulators like NICE and the FDA — being that all patient data in the trial will be 10 years to as much as 17 years from respective randomizations. However, if this was the plan all along these past five or more years, I feel LP and LG should refund half their shares, because it was not consistent with their public communication over that time.

That’s very mature data, and very old investors.